Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 [Yahoo! Finance]
Context Therapeutics Inc. (CNTX)
Company Research
Source: Yahoo! Finance
“The FDA's clearance of our IND marks an important achievement for Context, allowing us to proceed with the Phase 1 clinical program for this potentially best-in-class CLDN6-targeting therapy,” said Martin Lehr, CEO of Context. “We look forward to the expected dosing of the first patient with CTIM-76 in the coming months, and we believe the Company is well-positioned to achieve key program milestones.” The Phase 1 clinical trial is expected to be an open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancer. The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability, and pharmacokinetics as well as anti-tumor activity by overall response rate, duration of response, and disease control rate. The study is expected to enroll up to 70 patients. About CTIM-76 CTIM-76 is a CLDN6 x CD3 T cell engaging bis
Show less
Read more
Impact Snapshot
Event Time:
CNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTX alerts
High impacting Context Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
CNTX
News
- Context Therapeutics Inc. (NASDAQ: CNTX) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $4.50 price target on the stock.MarketBeat
- Context Therapeutics Inc. (NASDAQ: CNTX) is now covered by analysts at Piper Sandler Companies. They set an "overweight" rating and a $4.50 price target on the stock.MarketBeat
- Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- Context Therapeutics Inc. (NASDAQ: CNTX) had its price target raised by analysts at HC Wainwright from $4.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Context Therapeutics Inc. (NASDAQ: CNTX) had its price target raised by analysts at Maxim Group from $4.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
CNTX
Analyst Actions
- 5/9/24 - Maxim Group
CNTX
Sec Filings
- 5/16/24 - Form D
- 5/13/24 - Form SC
- 5/10/24 - Form SC
- CNTX's page on the SEC website